To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

The Liposome Co.

(LIPO)

Mabon Securities analyst Marc Ostro started coverage with a "buy," describing LIPO as a market anomaly: a company with advanced-stage

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE